SLC5A2 and type 2 diabetes mellitus: Although another study found that sodium-glucose cotransporter 2 inhibitors could reduce serum asprosin levels in newly diagnosed T2DM patients [22], due to the small number of patients in this study who used sodium-glucose cotransporter 2 inhibitors, no correlation was found, and future studies should increase the sample size.